For nearly a decade the conventional formulation of memantine has been helpful for treating patients with AD, especially those with advanced stages of the disease. Treatment with memantine has been ...

This release is available in German. There is no scientific proof that patients with moderate or severe Alzheimer's disease benefit from drugs containing the agent memantine. This is the conclusion in ...

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Merz Pharmaceuticals GmbH announced today that NAMENDA XR (TM) (memantine hydrochloride) was approved by the U.S. Food and Drug ...

Memantine, a drug approved for the treatment of Alzheimer disease, appears safe and effective in patients with moderate to severe cases of the condition, according to a study in the January issue of ...

After the manufacturer of the Alzheimer's drug memantine submitted a supplementary analysis of study data, the German Institute for Quality and Efficiency in Health Care sees proof of a benefit of the ...

Please provide your email address to receive an email when new articles are posted on . Cognitive decline is one of the potential adverse effects of cranial radiation therapy in cancer patients. It ...

Some people with autism spectrum disorder (ASD) have abnormal levels of glutamate in the brain. New research led by Mass General Brigham focused on this neuron-activating chemical, suggesting that a ...

In the Treatment of Alzheimer’s Disease, Polypharmacy Increases Across Lines of Therapy, According to New Analysis from Decision Resources BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one ...

Forest and Merz Announce FDA Approval of NAMENDA XR for the Treatment of Moderate to Severe Dementia of the Alzheimer's Type NEW YORK, Jun 21, 2010 (BUSINESS WIRE ...